ASK REDCHAT ANYTHING ABOUT CITIUS PHARMACEUTICALS INC.
Citius Pharmaceuticals Inc. (NASDAQ: CTXR)
Listen to this Section
$0.59
+0.0047
(
+0.81% )
0.1K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| LYMPHIR (Denileukin Diftitox-cxdl, E7777)DetailsT-cell lymphoma |
Approved |
| Mino-LokDetailsCatheter related blood stream infections |
Phase 3 |
| Halo-Lido (CITI-102)DetailsHemorrhoids |
Phase 2b |
| Pembrolizumab (KEYTRUDA®) + LYMPHIR™DetailsSolid tumor/s |
Phase 1 |
Market Data
| Open |
$0.59 |
| Previous Close |
$0.58 |
| Volume |
0.1K |
| Market Cap |
$16.00M |
| Day Range |
$0.56 - $0.60 |
| 52 Week Range |
$0.48 - $2.19 |
| Shares Outstanding |
27.45M |
| Change % |
+0.81% |
| Net Change |
▲ 0.0047 |
| Insider Ownership |
-0.61% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2011 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased:
-3,219,498.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-10-12 |
Sale |
-550000.00 |
Mazur Leonard L |